A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2014

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Depression; Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms PD-Depression
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 30 Jun 2010 Additional trial locations (Romania, Russia, Ukraine) identified as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual end date (1 May 2008) added as reported by ClinicalTrials.gov.
    • 30 Apr 2009 Results published as an abstract in the proceedings of the 61st Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top